First-ever INTERCEPT pathogen-reduced platelet units produced in US
This development follows the Food and Drug Administration's approval of Cerus’ INTERCEPT Blood System for plasma and platelets that the company received in December 2014.
INTERCEPT is engineered to decrease the chance of spreading infections through transfusions. To do this, scientists can use INTERCEPT to inactivate a variety of pathogens like parasites, viruses and bacteria that can be found in donated blood samples.
“We believe that initiating the production of INTERCEPT platelet components is a significant milestone in improving blood safety,” Scott Bush, chief executive officer of SCBB, said. “Providing our hospitals with pathogen-reduced products is essential to reducing transfusion-transmitted infections, including sepsis. INTERCEPT platelets also present a potential opportunity for the hospitals we serve to streamline inventory and allow the release of platelets earlier for the needs of their patients by eliminating procedures such as gamma irradiation.”
INTERCEPT’s nucleic acid targeting mechanism eliminates transfusion threats like West Nile Virus, hepatitis B and C, bacteria and HIV. It is also effective against other emerging pathogens like malaria, dengue fever and Chikungunya.
“Having pathogen-reduced platelet components available in the U.S. is the first step in helping our blood center customers transform the safety and availability of the blood supply,” William "Obi" Greenman, Cerus president and chief executive officer, said. “We are proud to have collaborated with SunCoast in successfully implementing INTERCEPT, and we look forward to helping SunCoast provide pathogen-reduced components to its Southwest Florida hospitals.”